Verve Therapeutics Inc VERV
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if VERV is a good fit for your portfolio.
News
-
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
-
Verve Therapeutics Announces Appointment of Nia Tatsis, Ph.D., and Jodie Morrison to its Board of Directors
-
VERV Investors Have the Opportunity to Join Investigation of Verve Therapeutics, Inc. with the Schall Law Firm
-
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
-
Verve Therapeutics Announces Leadership Update
-
Verve Therapeutics to Participate in Upcoming Investor Conferences
-
Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2024 Financial Results
-
Verve Therapeutics Announces Dosing of First Patient in Heart-2 Phase 1b Clinical Trial Evaluating VERVE-102
Trading Information
- Previous Close Price
- $5.14
- Day Range
- $4.99–5.29
- 52-Week Range
- $4.59–21.04
- Bid/Ask
- $5.05 / $5.29
- Market Cap
- $440.82 Mil
- Volume/Avg
- 830,539 / 1.4 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 22.26
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Verve Therapeutics Inc is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol, a root cause of cardiovascular disease. The company views its operations as and manages its business in one operating segment operating exclusively in the United States.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 255
- Website
- https://www.vervetx.com
Comparables
Valuation
Metric
|
VERV
|
MORF
|
NGM
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 0.74 | 2.40 | 0.86 |
Price/Sales | 22.26 | — | 28.76 |
Price/Cash Flow | — | — | — |
Price/Earnings
VERV
MORF
NGM
Financial Strength
Metric
|
VERV
|
MORF
|
NGM
|
---|---|---|---|
Quick Ratio | 19.56 | 37.20 | 7.18 |
Current Ratio | 19.82 | 38.17 | 7.79 |
Interest Coverage | — | — | — |
Quick Ratio
VERV
MORF
NGM
Profitability
Metric
|
VERV
|
MORF
|
NGM
|
---|---|---|---|
Return on Assets (Normalized) | −25.18% | −18.85% | −49.51% |
Return on Equity (Normalized) | −31.95% | −19.43% | −57.34% |
Return on Invested Capital (Normalized) | −31.26% | −23.26% | −61.20% |
Return on Assets
VERV
MORF
NGM
Biotechnology Industry Comparables
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|---|
Novo Nordisk A/S ADR
NVO
| Vwjtglmpcl | Gsdp | $624.9 Bil | |||
Vertex Pharmaceuticals Inc
VRTX
| Skmychf | Cznvwb | $121.4 Bil | |||
Regeneron Pharmaceuticals Inc
REGN
| Yggzgkpl | Vdrfhd | $112.8 Bil | |||
Moderna Inc
MRNA
| Wrjgkrgdz | Wlhcl | $44.4 Bil | |||
Alnylam Pharmaceuticals Inc
ALNY
| Drpnctbx | Rbrdv | $31.5 Bil | |||
argenx SE ADR
ARGX
| Qlfkwvyg | Jhlp | $25.9 Bil | |||
BioNTech SE ADR
BNTX
| Gtnxbmq | Lhs | $19.2 Bil | |||
Biomarin Pharmaceutical Inc
BMRN
| Lmhmccmfd | Lqfbr | $15.4 Bil | |||
United Therapeutics Corp
UTHR
| Lqtvgxw | Xxx | $13.8 Bil | |||
Royalty Pharma PLC Class A
RPRX
| Pprklgjyx | Nxswhf | $11.7 Bil |